Page tree
Skip to end of metadata
Go to start of metadata

Project Scope

  • Define role of QTLs in QbD, in particular the relationship to CTQs (Critical to Quality Factors), Estimands and continuous quality improvement (CQI)
  • Discuss the use of QTLs in Early Development/small studies, bio equivalence and complex designs
  • Discuss examples of how to define QTLs, different methodologies and different parameters in use across the industry
  • Discuss difficulties and challenges of implementation of QTLs
  • Examine role of QTLs as part of the of the lessons learned (RCA) feedback loop
Project LeadsEmail
Andy Lawton (Risk Based Approach Ltd)w.a.lawton@aol.co.uk
Chris Wells (Roche)chris.wells.cw1@roche.com
Paula Rowley (PHUSE Project Assistant)

paula@phuse.global

Objectives & DeliverablesTimelines
PublicationsQ32021
White PaperQ32022

CURRENT STATUS Q12022

Drafted questionnaire, continued discussions with the team on QTLs and CTQs.

Working on first draft of the role of QTL in the QbD paper.

Project MembersOrganisation
Alicja MarkGenmab
Andrew McGowanRHO World
Andrzej KinasiewiczAstraZeneca
Anne LawrenceAbbVie
Ansalan StewartFDA
Arati TodkarTCS
Barbara SeiderZealand Pharma 
Chonna CampbellUnither Pharmaceuticals
Crupa KurienPfizer
Debra JendrasekDSI
Georgina WoodCyntegrity 
Heidi HoffmanGenentech
Jean MulindeFDA
Julie AppelNovo Nordisk
Karen BleichFDA
Kate TomlinsonPRISM
Katherine TaylorMerck
Kevin DouglassDSI
Linda Del PaggioGenentech
Lukasz BojarskiAstraZeneca
Lynne CesarioPfizer
Mary ArnouldAstellas
Project MembersOrganisation
Michael WalegaBristol Myers Squibb
Mireille LovejoyRoche
Monika MoerschBoehringer-Ingelheim
Mukesh BabuIndustry
Nathalie Van BorrendamJanssen Research & Development 
Nick Wells Syneos Health 
Paul BrownDanish Medicines Agency
Priti GuptaPfizer
Sally WynnNovartis 
Shalaka GadhaveTCS
Sheetal ChandaranaRoche
Steve Young CluePoints
Steven GilbertPfizer

Problem Statement

QTLs -  the role they play in defining quality within the QbD framework, their relationship to Critical to Quality factors, associated methodologies and the interpretation of them have not been fully defined in clinical development, in particular where early development/small studies, bio equivalence studies and complex designs are concerned.

Problem Impact

This will impact the whole clinical development process and allow the move away from perfection to a defined and achievable quality, from which continuous quality improvement can begin.

Terminology Example:

  • Target Product Profile (TPP)
    • Patient wants extended dosing from current BD product on market
  • Critical Quality Attribute (CQA)
    • Once a day dosing
  • Critical to Quality Factor (CTQ)
    • In early stage trials drug levels shown at 24 hours
    • In Phase 2-3 demonstrate efficacy
  • Quality Tolerance Limit
    • Pre-define what will be acceptable limits for acceptance
      • These QTL's will change at different stages




  • No labels